| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 158.3 | 182.3 | 124.9 |
| Other income | 5.4 | 6.4 | 5.2 |
| Total income | 163.7 | 188.8 | 130.1 |
| Profit before exceptional items & tax | 54.3 | 62.7 | 44.1 |
| Profit before tax | 54.3 | 62.7 | 44.1 |
| Net profit | 40.6 | 48.5 | 31.3 |
| Operating margin | 33.2% | 33.2% | 33.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +29.70% |
|---|---|
| Net profit, quarter on quarter | -16.30% |
| Revenue, year on year | +26.70% |
| Operating profit, year on year | +25.70% |
| Operating profit, quarter on quarter | -13.10% |
NSE results filing, NSE: SUDEEPPHRM. Figures extracted from the filing.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,164.90
- Market cap
- ₹13,157 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.0×Sector 50.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.
Sudeep Pharma Q4 FY26 Results: Net Profit ₹48.5 Cr, Up 9.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹48.5 Cr · +9.7% YoY